AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Cognitive

    Selank (10mg)

    Intranasal or subcutaneous1–3x daily10mg

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    🇷🇺 МЗ РФ

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Approved by select regulatory agencies — not FDA/EMA
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Available sizes:
    10mg
    Nasal Spray
    5mg

    Research monograph

    See the full Selank encyclopedia page with mechanism, evidence tier, related variants and research context.

    Open monograph
    Free Access

    How It Works

    Selank regulates BDNF, GABAergic transmission, and enkephalins, providing anxiolytic action without sedation or dependence.

    Quick Start

    • Typical dose: 250–500mcg intranasally or subcutaneously
    • Frequency: 1–3x/day
    • Storage: 2–8°C after reconstitution
    Detailed Protocol Data

    Dosing Table — Selank 10mg

    Educational only
    Vial Size— affects syringe units
    BAC Water2 mL
    Concentration5.00 mg/mL

    Route: Intranasal or subcutaneous | Frequency: 1–3x daily

    WeekDoseUnits (per injection)
    1–2
    250mcg
    5 Units (0.05 mL)
    3+
    500mcg
    10 Units (0.10 mL)

    The 10mg vial provides 20+ doses of 500mcg. Same dosing as the 5mg vial.

    Related compounds

    Reconstitution Steps

    1. Clean the stoppers with an alcohol wipe.
    2. Draw 2mL of bacteriostatic water.
    3. Inject slowly down the side of the vial.
    4. Gently swirl until fully dissolved.
    5. Store in the refrigerator (2–8°C).

    Protocol Overview

    • Larger vial for more economical long-term use.
    • Same dosing and protocol as the 5mg vial.
    • Tuftsin analogue — anxiolytic and immunomodulatory.

    Dosing Protocol

    • 250–500mcg, 1–3x/day intranasally or subcutaneously.
    • Cycle: 2–4 weeks on, 1–2 week break.
    • Combines with Semax for nootropic enhancement.
    • Break between cycles: After the cycle (2–4 weeks), a break of 2–4 weeks is recommended. The break prevents tolerance.

    Washout & Cycle Restart

    When can I restart?

    After the cycle (2–4 weeks), a break of 2–4 weeks is recommended. The break prevents tolerance.

    Minimum wait period: 2 weeks

    Storage Instructions

    • Reconstituted: 2–8°C, use within 21 days.
    • Powder: 2–8°C.

    Important Notes

    • Non-addictive, no tolerance.
    • No sedation or drowsiness.
    • Immunomodulatory — caution with autoimmune conditions.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • Anxiolysis without sedation
    • Cognitive enhancement
    • Immunomodulation
    • Increased BDNF

    Potential Side Effects:

    • Mild nasal dryness
    • Rare headache

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    🧬 Endocrine
    🟡 Moderate / Theoretical

    BDNF modulation & immunoregulation

    Selank modifies BDNF, IL-6, and immune markers. Long-term effects in humans unclear — very few studies beyond 30 days.

    📄 Bull Exp Biol Med 2008

    References

    1. Selank Anxiolytic — Zozulya AA, et al. Bull Exp Biol Med. 2001;131(4):315-317.
      View Source
    2. Selank and BDNF expression — Inozemtseva LS, et al. Bull Exp Biol Med. 2008;146(11):630-632.
      View Source
    3. Selank modulates GABA system — Seredenin SB, et al. Bull Exp Biol Med. 2002;133(6):560-563.
      View Source

    Recommended Supplements

    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Research-only
    FDA Status
    1
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    🇷🇺
    МЗ РФ
    Approved

    Anxiety disorders (2008)

    Approved in Russia (2008)

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Summary:
    1 Approvals
    0 PubMed
    0 Clinical Studies

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu